Vipidia is a new DPP-4 inhibitor

• Tatyana B. Morgunova
• Valentin V. Fadeev

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors, oral hypoglycemic agents, augment glucose-dependent insulin secretion and suppress glucagon levels through enhancement of the action of endogenous incretin. Treatment with DPP-4 inhibitors is generally well tolerated due to low risk of hypoglycemia, weight gain and other adverse events. Alogliptin is a newly developed DPP-4 inhibitor. Once-daily administration of alogliptin as either monotherapy or in combination with other oral antidiabetic drugs has a potent glucose-lowering effect. The cardiovascular safety of this drug has been confirmed in a recent randomized controlled trial. This article describes the efficacy and safety of alogliptin, and discusses the role of DPP-4 inhibitors in the treatment of type 2 diabetes.

Keywords:diabetes mellitus type 2, oral antidiabetic drugs, DPP-4 inhibitors, alogliptin

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)